AndreaBozzo/ceres-open-data-index huggingface dataset:
VIDA: a virus database system
 for the organization of animal virus genome open reading frames

VIDA is a new virus database that organizes open reading frames
 (ORFs) from partial and complete genomic sequences from animal viruses.
 Currently VIDA includes all sequences from GenBank for Herpesviridae,
 Coronaviridae and Arteriviridae. The ORFs are organized into homologous
 protein families, which are identified on the basis of sequence
 similarity relationships. Conserved sequence regions of potential functional
 importance are identified and can be retrieved as sequence alignments.
 We use a controlled taxonomical and functional classification for
 all the proteins and protein families in the database. When available,
 protein structures that are related to the families have also been
 included. The database is available for online search and sequence
 information retrieval at http://www.biochem.ucl.ac.uk/bsm/virus_database/VIDA.html.
Compound 528127: Pyrazine, 2-butyl-3,5-dimethyl-

Chemical compound data from PubChem database. IUPAC Name: 2-butyl-3,5-dimethylpyrazine. Molecular Formula: C10H16N2. Molecular Weight: 164.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529083: Methyl 2-(3-benzoylphenyl)propanoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-(3-benzoylphenyl)propanoate. Molecular Formula: C17H16O3. Molecular Weight: 268.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Washington  DC  Metropolitan Area Drug Study Household and Non-Household Populations (DC-MADSH-1991)

<p>The DC Metropolitan Area Drug Study (DC<em>MADS) was<br />
conducted in 1991, and included special analyses of homeless and<br />
transient populations and of women delivering live births in the DC<br />
hospitals. DC</em>MADS was undertaken to assess the full extent of the<br />
drug problem in one metropolitan area. The study was comprised of 16<br />
separate studies that focused on different sub-groups, many of which<br />
are typically not included or are under-represented in household<br />
surveys.The DC<em>MADS: Household and Non-household Populations<br />
examines the prevalence of tobacco, alcohol, and drug use among<br />
members of household and non-household populations aged 12 and older<br />
in the District of Columbia Metropolitan Statistical Area (DC<br />
MSA). The study also examines the characteristics of three<br />
drug-abusing sub-groups: crack-cocaine, heroin, and needle users. The<br />
household sample was drawn from the 1991 National Household Survey on<br />
Drug Abuse (NHSDA). The non-household sample was drawn from the<br />
DC</em>MADS Institutionalized and Homeless and Transient Population<br />
Studies. Data include demographics, needle use, needle-sharing, and<br />
use of tobacco, alcohol, cocaine, crack, inhalants, marijuana, hallucinogens, heroin, sedatives, stimulants, psychotherapeutics (non-medical use), tranquilizers, and analgesics.This study has 1 Data Set.</p>
COVID-19 State Profile Report - Wisconsin

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Compound 529930: Nimodipine M (dehydro-desmethoxyethyl, methyl ester)

Chemical compound data from PubChem database. IUPAC Name: 5-O-methyl 3-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate. Molecular Formula: C19H20N2O6. Molecular Weight: 372.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530538: 4-Butylbenzoic acid, pentadecyl ester

Chemical compound data from PubChem database. IUPAC Name: pentadecyl 4-butylbenzoate. Molecular Formula: C26H44O2. Molecular Weight: 388.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399849-T1: [Translated] DETERGENT BAGS

Single or multi-compartment detergent pouch having walls composed of a water-soluble or dispersible water-containing polymer film, the pouch having at least one compartment containing a liquid composition and preferably at least one compartment containing a hygroscopic powder composition characterised in that the liquid composition comprises a moisture regulator system such that at equilibrium at 40% relative humidity and 21.1° C. (70° F.) the amount of water in the film is within about 30%, preferably within about 10% of that of the native film.
Compound 529495: Insariotoxin

Chemical compound data from PubChem database. IUPAC Name: [11-acetyloxy-2-(acetyloxymethyl)-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-4-yl] 3-methylbutanoate. Molecular Formula: C24H34O9. Molecular Weight: 466.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529432: 5-Hexen-2-one, 5-methyl-3-ethenyl

Chemical compound data from PubChem database. IUPAC Name: 3-ethenylhex-5-en-2-one. Molecular Formula: C8H12O. Molecular Weight: 124.18. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD COVID-19 - Number of Cases by Affected Congregate Facility

<b>Summary</b>
<b>This layer has been DEPRECATED</b> (last updated 12/1/2021). This was formerly a weekly update.

The Outbreak-Associated Cases in Congregate Living data dashboard on coronavirus.maryland.gov was redesigned on 11/17/21 to align with other outbreak reporting. Visit https://opendata.maryland.gov/dataset/MD-COVID-19-Congregate-Outbreak/ey5n-qn5s to view Outbreak-Associated Cases in Congregate Living data as reported after 11/17/21.

Cases at Maryland facilities where at least one confirmed case of COVID-19 is present for the reporting period.

<b>Description</b>
The MD COVID-19 - Number of Cases by Affected Congregate Facility data layer is a collection of nursing homes, assisted living facilities, group homes of 10 or more and state and local facilities where at least one positive COVID-19 test result has been reported for the reporting period. Data are reported to MDH by local health departments, the Department of Public Safety and Correctional Services and the Department of Juvenile Services. To appear on the list, facilities report at least one confirmed case of COVID-19 over the prior 14 days. Facilities are removed from the list when health officials determine 14 days have passed with no new cases and no tests pending. The list provides a point-in-time picture of COVID-19 case activity among these facilities. Numbers reported for each facility listed reflect totals ever reported for cases. Data are updated once weekly.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Patent AT-E401304-T1: [Translated] CATIONIC SUBSTITUTED DIPHENYLAZETIDINONES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND THEIR USE

The invention relates to compounds of formula (I), in which R1, R2, R3, R4, R5 and R6 are defined as cited, in addition to their physiologically compatible salts. The compounds are suitable for use e.g. as hypolipidaemics.
Compound 526068: 1-Docosanol, 20-methyl, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl(20-methyldocosoxy)silane. Molecular Formula: C26H56OSi. Molecular Weight: 412.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526560: 4-chloro-1-N-methyl-2-N-phenylbenzene-1,2-diamine

Chemical compound data from PubChem database. IUPAC Name: 4-chloro-1-N-methyl-2-N-phenylbenzene-1,2-diamine. Molecular Formula: C13H13ClN2. Molecular Weight: 232.71. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E40008-T1: [Translated] DEVICE FOR MEASUREMENT OF FLUORESCENCE, TUBACITY, LUMINESCENCE OR ABSORPTION.

The invention is concerned with equipment by means of which it is possible to measure the fluorescence, luminescence, turbidity, and absorption of a liquid sample. The sample is placed in a cylindrical cuvette provided with a transparent bottom. The light is passed into the cuvette by means of optical fibres along the centre axis of the cuvette. The equipment additionally includes an optical system whose optical axis coincides with the centre axis of the cuvette, as well as a light detector. It is an essential feature of the equipment that a substantially equal proportion of the light departing from each volume element of the sample is collected for detection, by means of the total reflection from the walls of the cuvette, through the optical system to the light detector, and that the optical system also collimates the light passed into the cuvette.
Influenza Vaccination Coverage, Citywide

Chicago residents who are up to date with influenza vaccines, based on the reported address, race-ethnicity, sex, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE).

“Up to date” refers to individuals aged 6 months and older who have received 1+ doses of influenza vaccine during the current season, defined as the beginning of July (MMWR week 27) through the end of the following June (MMWR week 26). 

Data Notes:

Weekly cumulative counts and coverage percentages of people up to date are shown for each combination of race-ethnicity, sex, and age group. Note that race-ethnicity, age, and sex all have an option for “All” so care should be taken when summing rows. Weeks begin on a Sunday and end on a Saturday. 

Coverage percentages are calculated based on the cumulative number of people in each race-ethnicity/age/sex population subgroup who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller demographic groupings with smaller populations. Additionally, the medical provider may report incorrect demographic information for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage. All coverage percentages are capped at 99%.

The Chicago Department of Public Health (CDPH) uses the most complete data available to estimate influenza vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Influenza vaccine administration is not required to be reported in Illinois, except for publicly funded vaccine (e.g., Vaccines for Children, Section 317). Individuals may receive vaccinations that are not recorded in I-CARE, such as those administered in another state, or those administered by a provider that does not submit data to I-CARE, causing underestimation of the number individuals who received an influenza vaccine for the current season. 

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to influenza, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=flu.
 
Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau 2020 Decennial Census
National Directory of Drug and Alcohol Abuse Treatment Facilities - 1994

The National Directory of Drug and Alcohol Abuse Treatment Programs 1994 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 1993 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 1993 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
Klippel-Feil syndrome – the risk of cervical spinal cord injury: A case report

Background
          Klippel-Feil syndrome is defined as congenital fusion of two or more cervical vertebrae and is believed to result from faulty segmentation along the embryo's developing axis during weeks 3–8 of gestation. Persons with Klippel-Feil syndrome and cervical stenosis may be at increased risk for spinal cord injury after minor trauma as a result of hypermobility of the various cervical segments. Persons with Klippel-Feil Syndrome often have congenital anomalies of the urinary tract as well.
        
        
          Case presentation
          A 51-year male developed incomplete tetraplegia in 1997 when he slipped and fell backwards hitting his head on the floor. X-rays of cervical spine showed fusion at two levels: C2 and C3 vertebrae, and C4 and C5 vertebrae. Intravenous urography (IVU) revealed no kidneys in the renal fossa on both sides, but the presence of crossed, fused renal ectopia in the left ilio-lumbar region. This patient had a similar cervical spinal cord injury about 15 years ago, when he developed transient numbness and paresis of the lower limbs following a fall.
        
        
          Discussion and Conclusion
          1) Persons with Klippel-Feil syndrome should be made aware of the increased risk of sustaining transient neurologic deterioration after minor trauma if there is associated radiographic evidence of spinal stenosis.
          2) Patients with Klippel-Feil syndrome often have congenital anomalies of the urinary tract. Our patient had crossed, fused, ectopia of kidney.
          3) When patients with Klippel-Feil syndrome sustain tetraplegia they have increased chances of developing urinary tract calculi. Treatment of kidney stones may pose a challenge because of associated renal anomalies.
          4) Health professionals caring for cervical spinal cord injury patients with Klippel-Feil syndrome and renal anomalies should place emphasis on prevention of kidney stones. A large fluid intake is recommended for these patients, as a high intake of fluids is still the most powerful and certainly the most economical means of prevention of nephrolithiasis.
Compound 527289: Pentanoic acid, 4-methyl-, (2E)-3,7-dimethyl-2,6-octadienyl ester

Chemical compound data from PubChem database. IUPAC Name: 3,7-dimethylocta-2,6-dienyl 4-methylpentanoate. Molecular Formula: C16H28O2. Molecular Weight: 252.39. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
AFCARS Technical Bulletin #20 - Questions and Answers

This webinar was the first session in the AFCARS Final Rule Training Series. This webinar provides an on the overview of Technical Bulletin 20, published October 29, 2020.  It includes a brief description and provides examples for the AFCARS 2020 out-of-home care and adoption and guardianship assistance data elements on the final rule.  It also provided guidance and direction to questions submitted on prior webinars.

Metadata-only record linking to the original dataset. Open original dataset below.
Atorvastatin calcium

Atorvastatin Calcium is a prescription medication used to lower cholesterol and triglyceride levels in the blood, reducing the risk of heart disease and stroke. Available as oral tablets in strengths of 10 mg, 20 mg, 40 mg, and 80 mg, it's a generic version of a statin drug. Manufactured by Cipla USA Inc. and others under ANDA205519. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400002-T1: [Translated] METHOD FOR PRODUCING A WEDGE-FREE ADHESIVE JOINT

The inventive method for the wedge-free bonding of planar surfaces comprises, in essence, a concluding phase involving bringing the surfaces to be bonded closer together. During this phase, the surfaces are brought closer together essentially by means of capillary forces and, optionally, with the aid of gravity. It is advantageous, before the actual bonding process, to parallelly align the surfaces to be bonded by simply placing one component atop the other. This enables, once adhesive (11) has been applied to the center of the first surface, the second surface, in the initial phase, to be quickly advanced toward the first surface up to a distance of 0.5 mm therefrom. In the intermediate phase of bringing the surfaces closer together, a slow average speed is selected in order to prevent the formation of bubbles once the adhesive comes into contact with the second surface.
Cytokine mRNA and protein expression in primary-culture and repeated-passage synovial fibroblasts from patients with rheumatoid arthritis

Constitutive mRNA expression and secretion of proinflammatory and anti-inflammatory cytokines was comparatively analyzed in rheumatoid arthritis (RA) synovial fibroblasts (SFB), isolated from primary culture or derived by repeated passage; normal-skin fibroblasts were used as controls. First-passage RA-SFB (n = 3) secreted large amounts of IL-6 (15,800 ± 2,110 pg/ml; mean ± SEM), but only limited amounts of tumor necrosis factor (TNF)-α (22.1 ± 1.1 pg/ml) or IL-10 (35.7 ± 34.2 pg/ml; only one of three samples was positive). IL-1β, IL-15, and IL-18 were not detectable at the protein level and showed very low mRNA levels by semiquantitative RT-PCR. In repeated-passage RA-SFB (tenth passage), protein secretion was significantly lower for IL-6 (one-twentieth of the initial level) and TNF-α (two-thirds), and markedly reduced for IL-10 (one-quarter, with only one of three samples positive). While the decrease of IL-10 protein from first to tenth passage was paralleled by a corresponding decrease of mRNA, the relative mRNA levels for IL-6 and TNF-α were actually increased (20-fold and 300-fold, respectively), indicating post-transcriptional and/or post-translational regulation of these cytokines. Due to highly variable levels among individual patients, however, no significant differences were observed for any cytokine mRNA between primary-culture and repeated-passage RA-SFB (ninth passage). Likewise, no significant differences were detectable between RA-SFB and normal-skin fibroblasts (primary-culture and repeated-passage). By producing high amounts of IL-6 and limited amounts of TNF-α, RA-SFB may contribute to the (im)balance of proinflammatory and anti-inflammatory cytokines in the inflamed joint.
Compound 529358: Asp, N-isoBOC TBDMS

Chemical compound data from PubChem database. IUPAC Name: bis[tert-butyl(dimethyl)silyl] 2-(2-methylpropoxycarbonylamino)butanedioate. Molecular Formula: C21H43NO6Si2. Molecular Weight: 461.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399726-T1: [Translated] CONTAINER FOR TRANSPORTING AND STORING A RADOM

The container has a planar base (B) formed of a rectangular pace plate whose two corners are truncated. A cover (C) has lower peripheral walls (4, 4`) following the base contour. A summit portion (6) is placed at the proximity of the top of a radome. The walls and the portion (6) are connected to sides corresponding to sides of a rectangle, by an inclined panel (5) provided at the immediate neighborhood of the radome. The cover has an inner side covered by strips made of a foam type absorbing material. The lateral walls of the cover have handles freely rotated in a hinge.
Irinotecan hydrochloide

Irinotecan Hydrochloride is a generic chemotherapy drug used to treat certain cancers, such as colorectal cancer. It works by inhibiting cancer cell growth and is administered intravenously as an injection. Available in strengths like 20 mg/mL, it's a prescription medication manufactured by companies like Xiromed LLC. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E399714-T1: [Translated] MACHINE AND METHOD FOR PACKAGING

A packaging method and apparatus wherein each product (P) is packaged by capturing the product in flexible packaging material. The packing apparatus includes a product detector (86) for detecting the presence or absence of a product to be packaged. The detection of the product may cause the advancement of packaging material (22,24) and the product through a nipping station (70,72) to form a package. The failure to detect a product may cause the advancement of the packaging material to stop and conserve packaging material until a product is detected. The product detector (86) is a light-sensitive sensor trained to detect a difference in light passing through the first web.